

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10588627
	Filing Date		2008-10-15
	First Named Inventor	Laura EGGINK	
	Art Unit	4854 1647	
	Examiner Name	Kosar, Andrew D Saoud	
	Attorney Docket Number	004908.00049	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5677276		1997-10-14	Dickerson et al.	
	2	5753481		1998-05-19	Niwa et al.	
	3	5910310		1999-06-08	Heinen et al.	
	4	5919998		1999-07-06	Bandurski et al.	
	5	6159937		2000-12-12	Larsen et al.	
	6	6193981		2001-02-27	Goldstein	
	7	6498020		2002-12-24	Walker et al.	
	8	7105481		2006-09-12	Uutela et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10588627
Filing Date	2008-10-15
First Named Inventor	Laura EGGINK
Art Unit	1654
Examiner Name	Kosar, Andrew D
Attorney Docket Number	004908.00049

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030073637		2003-04-17	Uutela et al.	
	2	20040031072		2004-02-12	La Rosa et al.	
	3	20040123343		2004-06-24	La Rosa et al.	
	4	20040248192		2004-12-09	Marchalonis et al.	
	5	20050063937		2005-03-24	Li et al.	
	6	20060024668		2006-02-02	Hock	
	7	20060078535		2006-04-13	Livant, Donna	
	8	20060148093		2006-07-06	Gygi et al.	
	9	20060160730		2006-07-20	Cuttitta et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10588627
Filing Date	2008-10-15
First Named Inventor	Laura EGGINK
Art Unit	1654
Examiner Name	Kosar, Andrew D
Attorney Docket Number	004908.00049

10	20060189538		2006-08-24	Secombes et al.	
11	20060269519		2006-11-30	Chen et al.	
12	20060287234		2006-12-21	Breen et al.	
13	20070003542		2007-01-04	Zimmerman et al.	
14	20070021342		2007-01-25	Breen et al.	
15	20070149475		2007-06-28	Murray et al.	
16	20070154448		2007-07-05	Reid et al.	
17	20080102076		2008-05-01	Eggink et al.	
18	20090041793		2009-02-12	Eggink et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	---------------------------	------------------------	------------------	---	--	----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10588627
Filing Date	2008-10-15
First Named Inventor	Laura EGGINK
Art Unit	1654
Examiner Name	Kosar, Andrew D
Attorney Docket Number	004908.00049

1	03/091275	WO		2003-11-06	Savarino, Andrea		<input type="checkbox"/>
2	04/011650	WO		2004-02-05	Intercell AG		<input type="checkbox"/>
3	05/087793	WO		2005-09-22	Arizona Board of Regents		<input type="checkbox"/>
4	06/063028	WO		2006-06-15	Arizona Board of Regents		<input type="checkbox"/>
5	2006/105021	WO		2006-10-05	Tolerrx, Inc.		<input type="checkbox"/>
6	2290722	CA		2001-06-08	Novopharm Biotech		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	CHARGELEGUE et al., "A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load in Vivo", Journal of Virology, 72 (3):2040-2046 (March 1998).	<input type="checkbox"/>
	2	CHERSI et al., "Specifications of rabbit antisera to multiple antigen (MAP) peptides", urnal of Biosciences, 50 (9-10):735-738 (September 1, 1995) ABSTRACT ONLY.	<input type="checkbox"/>
	3	CIESIELSKI et al., "Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat giloma model", Cancer Immunol Immunother, 54:107-119 (2005).	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10588627
Filing Date	2008-10-15
First Named Inventor	Laura EGGINK
Art Unit	1654
Examiner Name	Kosar, Andrew D
Attorney Docket Number	004908.00049

4	EGGINK et al., "A biologically active peptide mimetic of N-acetylgalactosamine/galactose", BMC Research Notes, 2:23 (2009).	<input type="checkbox"/>
5	G.FÄTKENHEUER et al., "Efficacy of Short-Term Monotherapy with Maraviroc, a New CRC5 Antagonist, in Patients Infected with HIV 1," Nature Med (2005), Vol. 11, pp. 1170-1172.	<input type="checkbox"/>
6	J. COHEN, "Hope on New AIDS Drugs, but Breast-Feeding Strategy Backfires," Science (2007), Vol. 315, pp. 1357.	<input type="checkbox"/>
7	J. STOVER et al., "The Global Impact of Scaling up HIV/AIDS Prevention Programs in Low-and Middle-Income Countries," Science (2006) Vol. 311, pp. 1474-1476.	<input type="checkbox"/>
8	MANKI et al., "Vaccination with Multiple Antigen Peptide as Rejection Antigen Peptide in Murine Leukemia", Cancer Research, 58:1960-1964 (May 1, 1998).	<input type="checkbox"/>
9	NICOLAUS, "Symbiotic Approach to Drug Design", Decision Making in Drug Research, pp. 173-186 (January 1, 1983).	<input type="checkbox"/>
10	OLSZEWSKA et al., "Protection against Measles Virus-Induced Encephalitis by Anti-mimotope Antibodies: The Rose of Antibody Affinity" Virology, 272(1):98-105 (June 20, 2000).	<input type="checkbox"/>
11	P.W. LATHAM, "Therapeutic Peptides Revisited," Nature Biotech (1999), vol. 17, pp. 755-757.	<input type="checkbox"/>
12	SARIG et al., "Telomeric and Tetraplex DNA Binding Properties of qTBP42: A Homologue of the CA/G Box Binding Protein CBF-A"; Biochemical and Biophysical Research Communications 1997, Volume 237, Number 3, pages 617-623	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Christine Saoud/	Date Considered	06/06/2011
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10588627
Filing Date	2008-10-15
First Named Inventor	Laura EGGINK
Art Unit	1654
Examiner Name	Kosar, Andrew D
Attorney Docket Number	004908.00049

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.